GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.
Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or.
HQ Team May 13, 2024: Merck has discontinued another cancer experimental immunotherapy treatment in patients with a severe form of melanoma due to.
HQ Team December 23, 2023: Moderna unveiled a skin cancer vaccine that demonstrated promising results in recent clinical trials. The vaccine, administered in.
HQ Team October 4, 2023: The US Food and Drug Administration has cleared Novavax’s updated Covid-19 vaccine for emergency use in adolescents 12.
HQ Team September 13, 2023: The US national public agency has recommended a COVID-19 vaccination policy where updated shots are given starting from.
HQ Team September 12, 2023: The US drug and medicine regulator, the FDA, approved COVID-19 vaccines made by Moderna Inc., Pfizer Inc., and BioNTech.
HQ Team September 11, 2023: Moderna Inc. announced a pact with Immatics NV, a clinical-stage biopharmaceutical company, to develop cancer therapies using a.
HQ Team April 8, 2023: Cancer vaccines will be ready by the end of this decade, according to pharmaceutical company Moderna’s chief medical.
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received.